A highly sensitive label-free assay for the determination of blood coagulation Factor XIII activity is demonstrated through the controlled assembly of peptide-functionalized gold nanoparticles (AuNPs). Activated Factor XIII catalyzes the formation of covalent crosslinking between peptide chains through ε-(γ-glutamyl)-lysine bonds leading to the aggregation of the AuNPs and consequently a red-shift of the localized surface plasmon resonance. The selective engineering of nanoscale order over AuNP crosslinking via the formation of isopeptide bonds provides a new approach toward the design of nanoassemblies with precise control on the molecular level. The colorimetric assay reported here provides direct qualitative and quantitative analysis of Factor XIII activity with a limit of detection of 0.01 U mL −1 .Factor XIII is a key enzyme in the blood coagulation pathway and has attracted significant attention due to its clinical importance in hemostasis, angiogenesis, wound healing, and tissue repair. 1-3 It belongs to the family of transglutaminases, and upon activation by thrombin and Ca 2+ catalyzes the formation of highly-organized intermolecular crosslinks between glutamine and lysine residues on fibrin molecules, forming stable blood clots that prevent excessive bleeding from damaged blood vessels. Pathological Factor XIII deficiency is associated with severe life-threatening bleeding, impaired wound healing, intracranial hemorrhage, recurrent pregnancy losses, and cardiovascular and gastrointestinal disorders. [4][5][6][7][8] Over the past decades, various detection methods have been developed for the determination of Factor XIII activity, including gel electrophoresis, 9 enzyme-linked immunosorbent assay (ELISA), 10 and fluorescence resonance energy transfer (FRET)-based assays. 11 In commercially available Factor XIII assays, two main detection approaches are used: (i) detection of ammonia released during the transglutaminase reaction 12,13 or (ii) incorporation of labeled amine (fluorescent-, radio-, or biotin-labeled) into a glutamine residue. [14][15][16] The former approach is rapid, but it has relatively low sensitivity; the latter approach is time consuming, difficult to standardize, and often overestimates the Factor XIII levels. 17,18 Hence, despite a significant level of development, these techniques still fail to address the great need for specific and sensitive assays that allow for the detection of Factor XIII activity at clinically relevant concentrations, and Factor XIII deficiency remains the most underdiagnosed bleeding disorder. [18][19][20]